Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Linperlisib in Recurrent/Refractory B-cell Malignancies
NCT04279405Phase 1Completed
- Sponsor
- Yingli Pharma
- Start
- Jun 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linperlisib in small lymphocytic lymphoma (SLL), Lymphoplasmacytic Lymphoma (LPL), marginal zone lymphoma (MZL) and 2 more, sponsored by Yingli Pharma. Primary endpoints: Adverse events evaluated by NCI CTCAE V5.0 at 2 years, Overall Response Rate at 2 years and 1 more. Started Jun 2020; status: completed.
02
Drugs
linperlisib
03
Conditions
small lymphocytic lymphoma (SLL)Lymphoplasmacytic Lymphoma (LPL)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04279405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04279405.